Literature DB >> 23356496

Morphological evidences of Bio-Oss® colonization by CD44-positive cells.

Pablo Galindo-Moreno1, Pedro Hernández-Cortés2, José Aneiros-Fernández3, Miguel Camara3, Francisco Mesa4, Stephen Wallace5, Francisco O'Valle6.   

Abstract

OBJECTIVES: Our objectives were to examine vascular and cellular colonization in anorganic bovine bone (ABB) after 6 months of healing in human maxillary sinus augmentation grafts.
MATERIAL AND METHODS: Fifty unilateral maxillary sinus augmentation procedures were performed on 50 consecutive patients. Bone cores were obtained through the implant receptor sites 6 months later and evaluated with morphological image analysis and immunohistochemical techniques.
RESULTS: Image analysis revealed a mean of 35.44 ± 16% vital bone, 31.66 ± 15% non-mineralized tissue, and 32.72 ± 25% remnant ABB particles. In our patients, neovascularization in 46.3% of cases was demonstrated within ABB particles 6 months after sinus floor augmentation surgery. Neovascularization of ABB particles was inversely related to age, directly to osteoclast number per mm², and not influenced by habits or disease. CD44-positive cells colonization was found in 74% of cases. An important correlation was found regarding CD44 expression and number of vessel in ABB particles (r = 0.624 P < 0.001, Pearson). Osteopontin expression was detected on the interstitial boundary of bone with ABB particles and within the osteocyte lacunae and bone canaliculi and was relationship with presence of CD44-positive cells inside ABB particles (r = 0.388, P = 0.046, Pearson).
CONCLUSION: In conclusion, images compatible with osteone colonized by osteocytes CD44 positive and neovascularization in ABB particles were observed after 6 months of graft maturation. These biologic events have not previously been morphologically and immunohistochemically documented.
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.

Entities:  

Keywords:  CD44; anorganic bovine bone; bone remodeling; intrasinus graft; neovascularization; osteocyte; osteopontin

Mesh:

Substances:

Year:  2013        PMID: 23356496     DOI: 10.1111/clr.12112

Source DB:  PubMed          Journal:  Clin Oral Implants Res        ISSN: 0905-7161            Impact factor:   5.977


  5 in total

Review 1.  Clinical Application of Mesenchymal Stem Cells and Novel Supportive Therapies for Oral Bone Regeneration.

Authors:  Miguel Padial-Molina; Francisco O'Valle; Alejandro Lanis; Francisco Mesa; David M Dohan Ehrenfest; Hom-Lay Wang; Pablo Galindo-Moreno
Journal:  Biomed Res Int       Date:  2015-05-12       Impact factor: 3.411

2.  Histomorphometric and immunohistochemical evaluation of collagen containing xenogeneic bone blocks used for lateral bone augmentation in staged implant placement.

Authors:  Alberto Ortiz-Vigón; Sergio Martinez-Villa; Iñaki Suarez; Fabio Vignoletti; Mariano Sanz
Journal:  Int J Implant Dent       Date:  2017-06-21

3.  In Vitro and In Vivo Study of a Novel Porcine Collagen Membrane for Guided Bone Regeneration.

Authors:  Eisner Salamanca; Chi-Yang Tsai; Yu-Hwa Pan; Yu-Te Lin; Haw-Ming Huang; Nai-Chia Teng; Che-Tong Lin; Sheng-Wei Feng; Wei-Jen Chang
Journal:  Materials (Basel)       Date:  2016-11-22       Impact factor: 3.623

4.  Maxillary sinus floor augmentation comparing bovine versus porcine bone xenografts mixed with autogenous bone graft. A split-mouth randomized controlled trial.

Authors:  Pablo Galindo-Moreno; Dario Abril-García; Ana Belen Carrillo-Galvez; Federico Zurita; Natividad Martín-Morales; Francisco O'Valle; Miguel Padial-Molina
Journal:  Clin Oral Implants Res       Date:  2022-03-03       Impact factor: 5.021

5.  A randomized, controlled, multicentre clinical trial of post-extraction alveolar ridge preservation.

Authors:  Eric Todd Scheyer; Rick Heard; Jim Janakievski; George Mandelaris; Marc L Nevins; Stephen R Pickering; Christopher R Richardson; Bryan Pope; Gregory Toback; Diego Velásquez; Heiner Nagursky
Journal:  J Clin Periodontol       Date:  2016-10-21       Impact factor: 8.728

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.